Important Decrease in Hospitalizations for Acute Diabetes Events Following FreeStyle Libre System Initiation in People with Type 2 Diabetes on Basal Insulin Therapy in France
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Aims/Hypothesis: Initiation of insulin therapy in people with type 2 diabetes (T2DM) may be necessary to achieve glycemic targets but is associated with acute diabetes events (ADEs), including severe hypoglycemia (SH) or diabetic ketoacidosis (DKA). We assessed the impact of initiating FreeStyle Libre® system (FSL) on hospitalizations for ADEs in people with T2DM on basal insulin only regimen±noninsulin antidiabetic drugs. Materials and Methods: A retrospective study of the French national Système National des Données de Santé reimbursement claims database (≈66 million French people) identified people with T2DM on basal insulin therapy receiving a first reimbursement of FSL between August 1, 2017 and December 31, 2018. Claims data for the 12 months before, and up to 24 months after FSL initiation, were analyzed. Hospitalizations for ADEs were identified, using ICD-10 codes as main or related diagnosis, for: SH events; DKA events; comas; and hyperglycemia-related admissions. Results: A total of 5933 people with T2DM on basal insulin therapy initiated FSL during the selection period. Of the patients, 78.9% were on basal insulin and other hypoglycemic agents. Among the 5933 patients identified, 2.01% had at least one hospitalization for any ADE in the year before FSL initiation, compared to 0.75% (1 year) and 0.60% (2 years). Reductions in ADEs were driven by 75% fewer DKA admissions, with a 44% reduction in SH admissions. These patterns of reduced ADEs persisted after 2 years, with a further 43% reduction in DKA rates. Conclusions/Interpretation: This study emphasizes the value of the FSL system in reducing ADEs in people with T2DM in France not on intensive insulin therapy and initially treated with basal-only insulin therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623 · cited 1×
“…studies indicate that improvements in measures of glycemic control in T2DM using FSL consider subjects on intensive insulin therapy using multiple daily injections (MDI) with insulin 2,6,8 or do not differentiate between those on MDI versus those on basal-insulin alone or on noninsulin therapy.”
Self-citationDeshmukh, H., Wilmot, E. G., Gregory, R., Barnes, D., Narendran, P., Saunders, S., Furlong, N., Kamaruddin, S., Banatwalla, R., Herring, R., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0738 · Cited by 175
Intermittently scanned continuous glucose monitoring for type 1 diabetes
Leelarathna, L., Evans, M. L., Neupane, S., Rayman, G., Lumley, S., Cranston, I., Narendran, P., Barnard-Kelly, K., Sutton, C. J., Elliott, R. A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2205650 · Cited by 174
Roussel, R., Riveline, J.-P., Vicaut, E., de Pouvourville, G., Detournay, B., Emery, C., Levrat-Guillen, F., & Guerci, B. (2021) · Diabetes Care · doi:10.2337/dc20-1690 · Cited by 173 · cited 7×
“9,10 The accumulating evidence suggests that FSL can be used in the same way to reduce long-term glucose exposure for adults with either T1DM or T2DM.”
InfluentialSelf-citationWada, E., Onoue, T., Kobayashi, T., Handa, T., Hayase, A., Ito, M., Furukawa, M., Okuji, T., Okada, N., Iwama, S., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001115 · Cited by 157
Wright, E. E., Kerr, M. S. D., Reyes, I. J., Nabutovsky, Y., & Miller, E. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0069 · Cited by 115
Kröger, J., Fasching, P., & Hanaire, H. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00741-9 · Cited by 90
Paris, I., Henry, C., Pirard, F., Gérard, A., & Colin, I. M. (2018) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.23 · Cited by 84
Walz, L., Pettersson, B., Rosenqvist, U., Deleskog, A., Journath, G., & Wändell, P. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s58781 · Cited by 75
Cited by
Continuous glucose monitoring for the routine care of type 2 diabetes mellitus
Ajjan, R. A., Battelino, T., Cos, X., Del Prato, S., Philips, J.-C., Meyer, L., Seufert, J., & Seidu, S. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00973-1 · Cited by 117
Aleppo, G., Hirsch, I. B., Parkin, C. G., McGill, J., Galindo, R., Kruger, D. F., Levy, C. J., Forlenza, G. P., Umpierrez, G. E., Grunberger, G., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0268 · Cited by 34
Conti, M., Massari, G., Meneghini, E., Pasquino, B., Agosti, B., Chinotti, F., Pintaudi, B., Girelli, A., & Bertuzzi, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030642 · Cited by 21
“…trials and real-world studies, showed that isCGM use was mainly associated with glycated haemoglobin improvement [8–16], a reduction of acute diabetes-related events (ADEs; i.e., severe hypoglycemia and diabetic ketoacidosis) [10] and a reduction of the rate of hospitalization for ADEs [9,10,12].”
BackgroundHarris, S., Cimino, S., Nguyen, Y., Szafranski, K., & Poon, Y. (2025) · Diabetes Therapy · doi:10.1007/s13300-024-01677-5 · Cited by 12
“…the T2DM non-insulin group, rates of DKA and SHE for SMBG were based on Danish real-world evidence [30] and a meta-analysis of population-based studies [31], respectively, and were assumed to be reduced with FreeStyle Libre to the same degree as in the T2DM basal insulin group in RELIEF [13, 29].”
Ratzki-Leewing, A., Harris, S. B., Rabasa-Lhoret, R., & Poon, Y. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0609 · Cited by 3
Metadata
- Authors
- Guerci, B., Roussel, R., Levrat-Guillen, F., Detournay, B., Vicaut, E., De Pouvourville, G., Emery, C., & Riveline, J.-P.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2023-01-01
- Volume
- 25
- Issue
- 1
- Pages
- 20-30
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W4295885818
- Cited by
- 69
- References
- 14
- FWCI
- 8.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Important Decrease in Hospitalizations for Acute Diabetes Events Following FreeStyle Libre System Initiation in People with Type 2 Diabetes on Basal Insulin Therapy in France. https://app.cochat.ai/papers/10.1089/dia.2022.0271
- The paper
- Guerci, B., Roussel, R., Levrat-Guillen, F., Detournay, B., Vicaut, E., De Pouvourville, G., Emery, C., & Riveline, J.-P. (2023). Important Decrease in Hospitalizations for Acute Diabetes Events Following FreeStyle Libre System Initiation in People with Type 2 Diabetes on Basal Insulin Therapy in France. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2022.0271
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.